Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs

Open Access

1 June 2005

journal article
Published by American Society for Microbiology in Infection and Immunity

Vol. 73 (6) , 3814-3816
https://doi.org/10.1128/iai.73.6.3814-3816.2005

Abstract

Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induced unprecedented 100% protection of guinea pigs from high-dose aerosol challenge with Mycobacterium tuberculosis, suggesting a strategy for enhancing and prolonging the efficacy of BCG.

Keywords

This publication has 14 references indexed in Scilit:

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
Nature Medicine, 2004
Phase 1 Evaluation of 3 Highly Immunogenic Prime‐Boost Regimens, Including a 12‐Month Reboosting Vaccination, for Malaria Vaccination in Gambian Men
The Journal of Infectious Diseases, 2004
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara
The Journal of Immunology, 2003
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
Nature Medicine, 2003
A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis
Infection and Immunity, 2003
BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies
The Lancet, 2002
Recombinant bacillus Calmette–Guérin (BCG) vaccines expressing theMycobacterium tuberculosis30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model
Proceedings of the National Academy of Sciences, 2000
Global Epidemiology of Tuberculosis
JAMA, 1995
Efficacy of BCG Vaccine in the Prevention of Tuberculosis
JAMA, 1994
BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.
BMJ, 1977